Latest news with #LEQSELVITM
Time of India
15-07-2025
- Business
- Time of India
Sun Pharma shares in focus following US launch of LEQSELVITM, settlement with Incyte Corporation
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Sun Pharmaceutical Industries are expected to remain in focus on Tuesday, July 15, after the company announced two significant developments regarding its oral treatment for severe alopecia areata, LEQSELVITM (deuruxolitinib), in the United a regulatory filing on Monday, Sun Pharma informed that it has entered into a settlement and license agreement with Incyte Corporation about the litigation surrounding litigation had been pending before the United States District Court for the District of New Jersey. Under the terms of the agreement, both Sun Pharma and Incyte will mutually release each other from all claims that were raised or could have been raised in the part of the settlement terms, Incyte has granted Sun Pharma a limited, non-exclusive license, along with certain other related patents pertaining to oral deuruxolitinib for specific non-hematology-oncology indications, including alopecia areata, within the United consideration for the settlement and the license granted, Sun Pharma will make an upfront payment to Incyte, along with ongoing royalty payments that will continue until the expiry of the relevant patents. The company clarified that the other specific terms of the agreement remain parallel, Sun Pharma also announced the commercial launch of LEQSELVITM (deuruxolitinib) 8 mg tablets in the United States. According to the official announcement, the drug is now available nationwide for prescription to healthcare providers and patients suffering from severe alopecia areata, offering a new treatment option in this is indicated for the treatment of adult patients diagnosed with severe alopecia the importance of this launch, Sun Pharma stated that treatment options for patients living with severe alopecia areata in the U.S. remain limited, underscoring the need for therapies such as company further disclosed that the drug had demonstrated promising clinical trial results. Specifically, one-third of patients treated with LEQSELVITM regained almost all of their hair by Week 24 of 3% of patients achieved 80% or more scalp coverage in as early as eight weeks.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Economic Times
15-07-2025
- Business
- Economic Times
Sun Pharma shares in focus following US launch of LEQSELVITM, settlement with Incyte Corporation
Shares of Sun Pharmaceutical Industries are expected to remain in focus on Tuesday, July 15, after the company announced two significant developments regarding its oral treatment for severe alopecia areata, LEQSELVITM (deuruxolitinib), in the United States. ADVERTISEMENT In a regulatory filing on Monday, Sun Pharma informed that it has entered into a settlement and license agreement with Incyte Corporation about the litigation surrounding LEQSELVITM. The litigation had been pending before the United States District Court for the District of New Jersey. Under the terms of the agreement, both Sun Pharma and Incyte will mutually release each other from all claims that were raised or could have been raised in the litigation. As part of the settlement terms, Incyte has granted Sun Pharma a limited, non-exclusive license, along with certain other related patents pertaining to oral deuruxolitinib for specific non-hematology-oncology indications, including alopecia areata, within the United consideration for the settlement and the license granted, Sun Pharma will make an upfront payment to Incyte, along with ongoing royalty payments that will continue until the expiry of the relevant patents. The company clarified that the other specific terms of the agreement remain parallel, Sun Pharma also announced the commercial launch of LEQSELVITM (deuruxolitinib) 8 mg tablets in the United States. According to the official announcement, the drug is now available nationwide for prescription to healthcare providers and patients suffering from severe alopecia areata, offering a new treatment option in this space. ADVERTISEMENT LEQSELVITM is indicated for the treatment of adult patients diagnosed with severe alopecia the importance of this launch, Sun Pharma stated that treatment options for patients living with severe alopecia areata in the U.S. remain limited, underscoring the need for therapies such as LEQSELVITM. ADVERTISEMENT The company further disclosed that the drug had demonstrated promising clinical trial results. Specifically, one-third of patients treated with LEQSELVITM regained almost all of their hair by Week 24 of 3% of patients achieved 80% or more scalp coverage in as early as eight weeks. ADVERTISEMENT Also read: Lack of short selling in Indian markets causing potential market distortions: Zerodha's Nithin Kamath (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
